Summary
Abbott Laboratories (ABT) has announced the completion of its significant acquisition of the pharmaceutical and diagnostics businesses of the Solvay Group. This strategic move, finalized on February 15, 2010, for an initial payment of EUR 4.5 billion (approximately $6.2 billion) in cash, significantly expands Abbott's global reach and therapeutic portfolio. The acquired business encompasses a broad range of medical products in key areas such as neuroscience, cardiometabolic diseases, influenza vaccines, gastroenterology, and women's and men's health. The transaction also includes potential milestone payments of up to EUR 300 million if certain sales targets are achieved between 2011 and 2013, indicating Abbott's optimism for the future performance of these newly integrated assets.
Key Highlights
- 1Abbott Laboratories completed the acquisition of Solvay Group's pharmaceutical and diagnostics businesses on February 15, 2010.
- 2The total initial purchase price was EUR 4.5 billion, approximately $6.2 billion, funded by Abbott's existing cash reserves.
- 3The acquisition significantly broadens Abbott's therapeutic areas, including neuroscience, cardiometabolic, vaccines, gastroenterology, and men's/women's health.
- 4Additional payments of up to EUR 300 million are contingent upon the acquired business meeting certain sales milestones between 2011 and 2013.
- 5The transaction includes the transfer of certain intercompany arrangements related to the acquired businesses.
- 6The filing incorporates by reference the original Stock and Asset Purchase Agreement from September 26, 2009, and an amendment dated February 15, 2010.
- 7A press release announcing the completion of the acquisition was issued on February 16, 2010.